个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共38条记录   Is It Downhill from Here? Eliminating Leukemic Stem Cells and Curing Chronic Myeloid Leukemia [作者：Smith, CC; Shah, NP,期刊：Clinical Cancer Research, 页码：6605-6607 , 文章类型： Editorial Material，,卷期：2011年17-21] Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (a), followed by a slow decline (b). The rate of b decrease is consistent with decli... Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma [作者：Kim, SW; Rai, D; Aguiar, RCT,期刊：Clinical Cancer Research, 页码：6723-6732 , 文章类型： Article，,卷期：2011年17-21] Purpose: Resistance to glucocorticoid (GC) is a significant problem in the clinical management of lymphoid malignancies. Addressing this issue via a mechanistic understanding of relevant signaling pathways is more likely... A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas [作者：Rajan, A; Kelly, RJ; Trepel, JB; Kim, YS; Alarcon, SV; Kummar, S; Gutierrez, M; Crandon, S; Zein, WM; Jain, L; Mannargudi, B; Figg, WD; Houk, BE; Shnaidman, M; Brega, N; Giaccone, G,期刊：Clinical Cancer Research, 页码：6831-6839 , 文章类型： Article，,卷期：2011年17-21] Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.Methods: ... A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies [作者：Moroney, JW; Schlumbrecht, MP; Helgason, T; Coleman, RL; Moulder, S; Naing, A; Bodurka, DC; Janku, F; Hong, DS; Kurzrock, R,期刊：Clinical Cancer Research, 页码：6840-6846 , 文章类型： Article，,卷期：2011年17-21] Purpose: Liposomal doxorubicin (D) and bevacizumab (A) are active single agents in gynecologic and breast malignancies which share a resistance mechanism: upregulation of hypoxia inducible factor (HIF-1 alpha). We, there... Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial [作者：Brunsvig, PF; Kyte, JA; Kersten, C; Sundstrum, S; Muller, M; Nyakas, M; Hansen, GL; Gaudernack, G; Aamdal, S,期刊：Clinical Cancer Research, 页码：6847-6857 , 文章类型： Article，,卷期：2011年17-21] Purpose: We report two clinical trials in non-small cell lung cancer (NSCLC) patients evaluating immune response, toxicity, and clinical outcome after vaccination with the telomerase peptide GV1001: a phase II trial (CTN... Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group [作者：Villablanca, JG; London, WB; Naranjo, A; McGrady, P; Ames, MM; Reid, JM; McGovern, RM; Buhrow, SA; Jackson, H; Stranzinger, E; Kitchen, BJ; Sondel, PM; Parisi, MT; Shulkin, B; Yanik, GA; Cohn, SL; Reynolds, CP,期刊：Clinical Cancer Research, 页码：6858-6866 , 文章类型： Article，,卷期：2011年17-21] Purpose: To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma.Experimental Design: Patients received 7 days of fenretinide: 2,475 mg/m... Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children [作者：Trame, MN; Bergstrand, M; Karlsson, MO; Boos, J; Hempel, G,期刊：Clinical Cancer Research, 页码：6867-6877 , 文章类型： Article，,卷期：2011年17-21] Purpose: To evaluate the best method for dosing busulfan in children, we retrospectively analyzed two different data sets from three different dosing regimens by means of population pharmacokinetics using NONMEM.Experime... Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer [作者：Hardy, NM; Mossoba, ME; Steinberg, SM; Fellowes, V; Yan, XY; Hakim, FT; Babb, RR; Avila, D; Gea-Banacloche, J; Sportes, C; Levine, BL; June, CH; Khuu, HM; Carpenter, AE; Krumlauf, MC; Dwyer, AJ; Gress, RE; Fowler, DH; Bishop, MR,期刊：Clinical Cancer Research, 页码：6878-6887 , 文章类型： Article，,卷期：2011年17-21] Purpose: Metastatic breast cancer (MBC) response to allogeneic lymphocytes requires donor T-cell engraftment and is limited by graft-versus-host disease (GVHD). In mice, type-II-polarized T cells promote engraftment and ... The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use [作者：Nieto, M; Borregaard, J; Ersboll, J; ten Bosch, GJA; van Zwieten-Boot, B; Abadie, E; Schellens, JHM; Pignatti, F,期刊：Clinical Cancer Research, 页码：6608-6614 , 文章类型： Article，,卷期：2011年17-21] On June 14, 2010, the European Commission issued a conditional marketing authorization valid throughout the European Union for pazopanib for the treatment of advanced renal cell carcinoma. Pazopanib is an antineoplastic ... Eribulin Mesylate [作者：Jain, S; Vahdat, LT,期刊：Clinical Cancer Research, 页码：6615-6622 , 文章类型： Article，,卷期：2011年17-21] Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U. S. Food and Drug Administration as third-line treatment of metastatic breast cancer refractory to anthracyc... MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond? [作者：McAllister-Lucas, LM; Baens, M; Lucas, PC,期刊：Clinical Cancer Research, 页码：6623-6631 , 文章类型： Article，,卷期：2011年17-21] The identification of mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) as a gene that is perturbed in the B-cell neoplasm MALT lymphoma, already more than a decade ago, was the starting point for an int... Achieving the Goals of Effective, Safe, and Individualized Cancer Care [作者：Roberts, SA; Karnes, EK; Allen, JD; Benner, JS; Sigal, EV; McClellan, M,期刊：Clinical Cancer Research, 页码：6632-6633 , 文章类型： Editorial Material，,卷期：2011年17-21] Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics [作者：Scher, HI; Nasso, SF; Rubin, EH; Simon, R,期刊：Clinical Cancer Research, 页码：6634-6640 , 文章类型： Article，,卷期：2011年17-21] A critical challenge in the development of new molecularly targeted anticancer drugs is the identification of predictive biomarkers and the concurrent development of diagnostics for these biomarkers. Developing matched d... A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Antitumor Mechanisms against Ovarian Cancer Cells [作者：Miyamoto, S; Iwamoto, R; Furuya, A; Takahashi, K; Sasaki, Y; Ando, H; Yotsumoto, F; Yoneda, T; Hamaoka, M; Yagi, H; Murakami, T; Hori, S; Shitara, K; Mekada, E,期刊：Clinical Cancer Research, 页码：6733-6741 , 文章类型： Article，,卷期：2011年17-21] Purpose: Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and plays a pivotal role in tumor progression in ovarian cancer. We developed an anti-HB-EGF monoclonal ant... TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy [作者：Lu, HL; Yang, Y; Gad, E; Inatsuka, C; Wenner, CA; Disis, ML; Standish, LJ,期刊：Clinical Cancer Research, 页码：6742-6753 , 文章类型： Article，,卷期：2011年17-21] Purpose: The therapeutic effect of trastuzumab monoclonal antibody (mAb) therapy has been shown to be partially dependent on functional natural killer (NK) cells. Novel agents that enhance NK cell function could potentia... TGF beta 1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo [作者：Bouquet, F; Pal, A; Pilones, KA; Demaria, S; Hann, B; Akhurst, RJ; Babb, JS; Lonning, SM; DeWyngaert, JK; Formenti, SC; Barcellos-Hoff, MH,期刊：Clinical Cancer Research, 页码：6754-6765 , 文章类型： Article，,卷期：2011年17-21] Purpose: To determine whether inhibition of TGF beta signaling prior to irradiation sensitizes human and murine cancer cells in vitro and in vivo.Experimental Design: TGF beta-mediated growth and Smad phosphorylation of ...